CSL Seqirus welcomes extended approval for iron treatment

Latest News

CSL Seqirus has confirmed that its intravenous (IV) iron treatment, FERINJECT, is now indicated in Australia for treating iron deficiency anaemia in children aged one to thirteen when oral iron preparations are ineffective or cannot be used.

The company said it can be prescribed to eligible patients following a healthcare professional's diagnosis of iron deficiency anaemia.

Iron deficiency anaemia occurs when the body does not have enough iron to produce haemoglobin. Common symptoms of iron deficiency anaemia include fatigue, dizziness, restlessness and loss of appetite.

Until now, FERINJECT was approved for adults and adolescents aged 14 and older for iron deficiency. The new approval means eligible patients 13 and under with iron deficiency anaemia can now receive FERINJECT treatment.

Iron deficiency is the most common nutritional deficiency worldwide and the leading cause of anaemia in children. In Australia, it has been estimated that approximately 8 per cent of preschool children, 12 per cent of pregnant women and 15 per cent of non-pregnant women are living with anaemia, with iron deficiency anaemia as a major cause.

According to Associate Professor Daniel Lemberg, paediatric gastroenterology senior staff specialist at Sydney Children's Hospital, treating iron deficiency is essential in helping those affected to live a full life.

“Iron deficiency is one of the most prevalent medical issues among Australian children. The news of another treatment option for children aged one to thirteen years when oral iron preparations are ineffective or cannot be tolerated is welcome news,” said Associate Professor Daniel Lemberg.

“Children may be at risk of developing iron deficiency, especially young adolescents who experience rapid growth and heavy menstrual bleeding. Supporting the health and growth of children impacted by this condition remains a key priority, and having an additional treatment option available for this age group is a positive step forward as we do just that,” said Associate Professor Daniel Lemberg.

Claire Morgan, CSL Seqirus medical director for pharmaceuticals, said, “Australians living with iron deficiency anaemia experience many symptoms that significantly impact their daily lives. The new indication for Ferinject for the treatment of iron deficiency anaemia in children will provide young Australians with access to an additional treatment option to help manage their symptoms and the burden of this condition.

“CSL Seqirus is committed to improving quality of life for children living with iron deficiency anaemia and this news is evidence of that.”